🇺🇸 FDA
Pipeline program

CM313 (SC)

FirstAHFujian456

Phase 2 small_molecule active

Quick answer

CM313 (SC) for Pemphigus Disease is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Pemphigus Disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials